摘要:
Helicobacter pylori-colonized Mongolian gerbils prepared by oral inoculation of a broth culture obtained from a liquid culture of Helicobacter pylori, to the Mongolian gerbils for intragastric colonization of Helicobacter pylori. These Mongolian gerbil models are useful for screening the therapeutic efficacies of drugs against Helicobacter pylori, as well as elucidation of pathology of Helicobacter pylori disease in humans. Moreover, the medium of the present invention for isolating Helicobacter pylori, which is supplemented with vancomycin, trimethoprim, amphotericin B, polymyxin B and 2,3,5-triphenyltetrazolium chloride, enables selective and efficient detection of Helicobacter pylori colonized in their Mongolian gerbils which have microorganisms living in stomach. A combined use of the above-mentioned Mongolian gerbil models and the medium for isolating Helicobacter pylori enables screening of an anti-Helicobacter pylori substance at an animal levels thereby enabling accurate prediction of clinical effects of the anti-Helicobacter pylori substance.
摘要:
The present invention relates to an agent for the prophylaxis and treatment of diseases caused by Helicobacter infections, which comprises (S)-1-cyclopropyl-1,4-dihydro-7-[2-(N,N-dimethylaminomethyl)morpholino]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof. The prophylactic and therapeutic agent of the present invention is effective even when used alone in a small dose for a short time, is almost free of problematic side effects such as tolerance and diarrhea, and is low toxic and capable of safe and ensured bacterial eradication. It is useful for the prophylaxis and treatment of diseases caused by Helicobacter infections, particularly, gastritis, gastric ulcer, duodenal ulcer, malignant lymphoma and gastric cancer.
摘要:
The present invention relates to a novel sulfonic acid derivative of hydroxamic acid or a pharmacologically acceptable salt thereof. More particularly, the present invention relates to a sulfonic acid derivative of hydroxamic acid or a pharmacologically acceptable salt thereof, which is useful as an inhibitor of lipopolysaccharides (LPS). In addition, the present invention relates to a novel intermediate compound useful for the synthesis of this sulfonic acid derivative of hydroxamic acid.